Stockreport

Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]

Rapport Therapeutics, Inc.  (RAPP) 
PDF Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026 RAP- 219 epilepsy portfolio expanded with new program in primary generalized tonic [Read more]